This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in node-positive melanoma patients but have limited power to determine if this benefit persists across various demographic factors. MATERIALS & METHODS: We assessed the impact of demographic factors on the survival benefit of adjuvant immunotherapy in a database of 38,189 node-positive melanoma patients using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: All assessed demographic factors other than race significantly impacted survival of node-positive melanoma patients in univariate analysis. In multivariable analysis, only the age group interacted with immunotherapy. CONCLUSION: Analysis of this large database of unselected node-positive melanoma patients demonstrated a positive survival benefit of immunotherapy across all demographic factors assessed and the impact was greater for patients 65 years of age and older.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ikeguchi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: